Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later — 13-year follow-up shows stable factor IX expression and low bleeding rates ...

Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.

HYMPAVZI has received regulatory approvals in the U.S. and in Europe for eligible patients living with hemophilia A without factor VIII inhibitors, or hemophilia B without factor IX inhibitors.

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for individuals aged 12 to <75 years living with hemophilia A or B with inhibitors.

Hemophilia can’t stop Central NY baseball star from historic high school career: ‘He’s really overcome it’ Updated: Jun. 19, 2025, 9:27 a.m. | Published: Jun ...

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and adolescents living with hemophilia A or B with inhibitors in a late-stage ...

(RTTNews) - Pfizer Inc. (PFE) Thursday reported positive topline results from the Phase 3 BASIS study of Hympavzi for adults and adolescents living with hemophilia A or B with inhibitors. The ...